Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.
Disclosed are neurosteroids and prodrugs thereof. Pharmaceutical formulations containing the neurosteroids and prodrugs are also disclosed. Additionally, methods of treating a condition, disorder, or disease using the neurosteroids, prodrugs, or pharmaceutical formulations are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, CNS injury, concussion, traumatic brain injury, depression, postpartum depression, epilepsy, seizure disorder, essential tremor, fragile X syndrome, and neurodegenerative disease.
C07J 7/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
3.
LIPID NANOPARTICLES CONTAINING NUCLEIC ACIDS ENCODING ENDONUCLEASES FOR TARGETING PHOSPHOFRUCTOKINASE (PFK) ENZYMES AND USES IN MANAGING CANCER
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventor
Teng, Yong
Li, Yamin
Abstract
Disclosed herein are compositions and methods for treating or preventing cancer. In certain embodiments, this disclosure relates to lipid nanoparticles (LNPs) comprising nucleic acids that encode endonuclease enzymes and guide RNA for uses in head, neck, or other cancer treatments. In certain embodiments, the endonuclease enzyme is a phosphofructokinase (PFK) enzyme.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed herein are methods of oxidizing a guanidine group comprising contacting a compound or peptide having a guanidine group with a 9,10-phenanthrenequinone or derivative providing compound with an aldehyde group in place of the guanidine group. In certain embodiments, the guanidine group is an arginine amino acid within a protein. In certain embodiments, this disclosure relates to compositions comprising 9,10-phenanthrenequinone derivatives as provided herein.
Disclosed are methods of treating, preventing, or reversing sepsis and comorbidities comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of or diagnosed with sepsis-associated organ failure, sepsis associated encephalopathy, sepsis associated acute kidney injury, sepsis induced cardiac dysfunction, sepsis induced acute respiratory distress, and/or hepato-splanchnic dysfunction.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
6.
SYSTEMS AND METHODS FOR QUANTITATIVE DIAGNOSIS OF ANEMIA
A smartphone-based hemoglobin (Hgb) assessment application quantitatively analyzes pallor in patient-sourced photos using image analysis algorithms to enable a noninvasive, accurate quantitative smartphone app for detecting anemia. A user takes a photo of his/her fingernail beds using the app and receives an accurate displayed Hgb level. Since fingernails do not contain melanocytes, the primary source of color of these anatomical features is blood Hgb. At the same time, quality control software minimizes the impact of common fingernail irregularities (e.g. leukonychia and camera flash reflection) on Hgb level measurement. Metadata recorded upon capturing the image is leveraged for determining a users' Hgb level thereby eliminating the need for external equipment. A personalized calibration of image data with measured Hgb levels improves the accuracy of the application.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
This invention relates to compositions comprising physiologic dendritic cells and at least one miRNA. The invention further relates to compositions comprising physiologic dendritic cells and at least one mRNA for use in vaccination.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
This disclosure relates to pentagalloyl glucose compositions and uses in managing microbial infections and compositions related thereto. In certain embodiments, this disclosure relates to compositions of pentagalloyl glucose. In certain embodiments, this disclosure relates to methods of treating or preventing a microbial infection, e.g., an antimicrobial resistant microbial infection, comprising administering to a subject in need thereof an effective amount of pentagalloyl glucose or salt thereof. In certain embodiments, the microbe is bacteria or fungi resistant to one or more antibiotic agents or antifungal agents.
Disclosed herein are nucleic acids and vectors encoding methioninase for uses in treating cancer. In certain embodiments, expression of methioninase is controlled using loxP sites and Cre enzymes allowing for cancer cell type targeting. In certain embodiments, this disclosure relates to method of treating cancer comprising administering an effective amount of a recombinant viral vector encoding methioninase in combination with administration of a Cre enzyme or nucleic acid or vector encoding the same to a subject in need thereof. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising nucleic acids and vectors encoding methioninase and/or a Cre enzyme as reported herein.
The present disclosure relates to anti-influenza activatable RNase guide sequences and their use in methods of treating, preventing, and/or detecting influenza infections. This disclosure is based on the discovery that through the use of unique guide RNA molecules, it is possible to target Cas13a to influenza and use the Cas13a RNase activity to degrade the Influenza virus and thereby treat flu.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
12.
Recombinant Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies
This disclosure relates to therapeutics containing recombinant IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 to a subject diagnosed with cancer and administering T cells expressing a chimeric antigen receptor to the subject. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 and a chimeric antigen receptor to a subject diagnosed with cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
This disclosure relates to bioink compositions for the fabrication of hydrogels or cell-laden hydrogel constructs comprising methacrylated polyethylene glycol and methacrylated gelatin. In certain embodiments, this disclosure relates to methods of fabricating cell-laden hydrogel constructs using bioink composition disclosed herein. In certain embodiments, cells are introduced into the hydrogel scaffold providing a cell-laden hydrogel construct.
Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are isolated prenatally, at birth, or after the subject's birth. The modified MSC may also express high levels von Willebrand factor protein.
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (USA)
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (USA)
THE SCRIPPS RESEARCH INSTITUTE (USA)
EMORY UNIVERSITY SCHOOL OF MEDICINE (USA)
Inventor
Olson, Steven H.
Jackson, Michael R.
Nalikezhathu, Anju
Kearney, Patrick
Dutta, Shubhankar
Garcia-Sastre, Adolfo
Schotsaert, Michael
Yoh, Sunnie M.
Chanda, Sumit K.
Tomalka, Jeffrey A.
Sekaly, Rafick
Abstract
Provided herein are compositions comprising a vaccine composition and an agent that induces innate immune responses in primary human monocyte derived dendritic cells (MDDCs) and methods of using the agent that induces innate immune responses in and activation of MDDCs to increase effectiveness of the vaccine.
C07C 335/26 - Y being a hydrogen or a carbon atom, e.g. benzoylthioureas
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C07D 229/02 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
C07D 319/16 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
16.
SYNTHESIS AND ANTIVIRAL ACTIVITY OF DIOXOLANE-DERIVED 7-DEAZAPURINE NUCLEOSIDE ANALOGS AND METHODS OF TREATING EPSTEIN BARR VIRUS (EBV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
EMORY UNIVERSITY (USA)
Inventor
Singh, Uma, S.
Sarafianos, Stefan, G.
Chu, Chung, K.
Abstract
The present invention is directed to novel dioxolane-derived 7-deazapurine nucleoside analogs, the antiviral activity of these compounds, pharmaceutical compositions thereof and methods of treating Epstein Barr Virus (EBV), Human Immunodeficiency Virus (HIV) infections and Multiple Sclerosis or reducing the likelihood of these disease states occurring in patients or subjects at risk for same, and inhibiting, resolving or ameliorating symptoms associated therewith.
C07D 473/16 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
Goods & Services
Print publications, namely, manuals, instructional
materials, and guided exercises in the field of meditation
and reflective practices. Educational services, namely, instruction and training in
meditation and reflective practices; conducting and guiding
contemplative exercises; providing online publications in
the field of meditation and reflective practices.
18.
COMPUTED TOMOGRAPHY (CT) SYSTEM FOR GENERATING A CT IMAGE OF A REGION OF INTEREST OF A SUBJECT AND AN INTERVENTIONAL DEVICE USING SPARSE-VIEW CT PROJECTION DATA DURING A CT-GUIDED INTERVENTIONAL PROCEDURE
A computed tomography (CT) system may acquire sparse-view CT projection data of a region of interest of a subject and an interventional device provided within the region of interest of the subject during a CT-guided interventional procedure by pulsing an X-ray source. The CT system may generate one or more time-resolved CT images of the region of interest and the interventional device using the sparse-view CT projection data and a reconstruction technique. The CT system may utilize the CT image of the region of interest and the interventional device during the CT-guided interventional procedure, such as by displaying the CT image via a display of the CT system or by providing the CT image to a robotic surgical system that is configured to perform the CT-guided interventional procedure.
This disclosure reports methods of improving tissue wound healing or growing tissues by using biodegradable graft compositions optionally comprising an exogenously added beneficial bacteria and optionally comprising exogenously added isolated macrophages or other cells. In certain embodiments, this disclosure relates to surgical methods of improving the healing of oral issues after a surgical intervention by implanting graft compositions reported herein on, in, or around the surgical site.
Georgia State University Research Foundation, Inc. (USA)
Emory University (USA)
Georgia Tech Research Corporation (USA)
Inventor
Sendi, Mohammad Sadegh Eslampanah
Calhoun, Vince
Gross, Robert
Abstract
A method for treating a patient comprises the steps of: receiving a set of information describing the patient, identifying a biomarker associated with a condition affecting the patient, determining a functional link between the biomarker and at least one modulation parameter by using an active learning framework, and applying the functional link to treat the condition in the patient by modulating at least one specific region of the patient.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
EMORY UNIVERSITY (USA)
Inventor
Kapfhamer, David, J.
Roberts, Joseph
Khan, Mohd, Nazir
Drissi, Moulay, Hicham
Abstract
Disclosed are methods of repairing bone fractures comprising administering a therapeutically effective amount of a composition comprising a nucleic acid sequence to a subject having a bone fracture, wherein the nucleic acid sequence comprises a Runx3- targeting miRNA. Disclosed are methods of promoting the transition from cartilaginous to bony callus comprising administering a therapeutically effective amount of a composition comprising a nucleic acid sequence to a site comprising a bone fracture, wherein the nucleic acid sequence comprises a Runx3 -targeting miRNA. Disclosed are methods of decreasing Runx3 expression comprising administering a therapeutically effective amount of a composition comprising a nucleic acid sequence to a site comprising a bone fracture, wherein the nucleic acid sequence comprises a Runx3 -targeting miRNA.
Disclosed herein are methods of managing cancer treatments using an anticancer agent and iron, heme, iron complexes, and/or iron salts. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering to a patient in need thereof an effective amount of a BCL-2 inhibitor in combination with iron, heme, iron complex, and/or iron salt. In certain embodiments, the cancer is a hematological malignancy. In certain embodiments, the iron complex is a heme iron complex.
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
Phosphate prodrugs of cannabinoids, with enhanced physicochemical, pharmacological, and/or pharmacokinetic properties, such as enhanced aqueous solubility and enhanced oral bioavailability are disclosed herein, as are pharmaceutical compositions comprising one or more of the same. Such compounds and compositions are useful for the treatment of diseases, disorders, and/or conditions where treatment with a cannabinoid may be useful, including pain, multiple sclerosis, and epilepsy.
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
A system may include a pump. A system may include a catheter including a plurality of spaced apart orifices. A system may include a controller operatively coupled to the catheter, the controller being configured to control fluid flow to the catheter.
Antisense oligonucleotides that specifically bind an ELAV-like RNA-binding protein 3 (ELAVL3) cryptic exon DNA, pre-mRNA, mRNA, or nascent RNA sequence are provided. Methods of making and using the same are also provided.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
29.
Chemokine CXCR4 Receptor Modulators and Uses Related Thereto
The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (Republic of Korea)
Inventor
Yoon, Young-Sup
Kim, Kyung Hee
Han, Ji Woong
Jung, Cholomi
Lee, Shin-Jeong
Abstract
Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
31.
Uses of Hydroimidazopyridopyrimidinone Derivatives for Managing Aneurysms or Other Vascular Conditions or Diseases
This disclosure relates to methods of treating or preventing aneurysms or other vascular diseases of conditions related thereto comprising administering an effective amount of a hydroimidazopyridopyrimidinone derivative or salt thereof to a subject in need thereof. In certain embodiments, the derivative comprises a 2,4,6,7,8,9-hexahydro imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1H)-one core structure comprising substituents. In certain embodiments, the compound is 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexa-hydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one (ONC201/TIC10), derivative, or salt thereof.
An apparatus for spoofing attack detection in a wireless system and a method of operation thereof. The apparatus includes a multi-antenna RF array, a beamformer, a preprocessor and a machine learning-based detector. The array produces signals in response to an RF signal from a transmitter having one or more transmitter beam patterns. The beamformer combines the signals using a receiver beam pattern to produce a received signal. The preprocessor produces feature vectors of an RF fingerprint, where a component of a feature vector is a strength of the received signal for a measured beam pattern pair, the beam pattern pair having a transmitter beam pattern and a receiver beam pattern, or a designated value for an unmeasured beam pattern pair. The detector is configured to detect a spoofing attack from an incomplete feature vector that has at least one component corresponding to an unmeasured beam pattern pair.
H04B 7/06 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas at the transmitting station
The implanted pressure sensors can non-invasively and stably measure intracranial pressure using MRI-compatible materials. In some examples, the implanted pressure sensor can include a fluid reservoir filled with a fluid. The sensor may also include a gas chamber filled with a gas and a gas-fluid interface. The interface may include a channel. The channel may have a first end and a second end. The channel may have a pattern that includes a plurality of linear segments connected by a plurality of junction segments. The fluid reservoir may be in flow communication with the gas-fluid interface. The gas chamber may be in flow communication with the gas-fluid interface and spaced separate from the gas-fluid interface.
A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
34.
BROADLY NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO DENGUE VIRUS
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (ICGEB) (India)
EMORY UNIVERSITY (USA)
Inventor
Reddy, Elluri Seetharami
Saini, Keshav
Chandele, Anmol
Kaja, Murali Krishna
Abstract
The present invention provides monoclonal antibodies against Dengue virus serotypes, which are capable of effectively neutralizing Dengue virus serotypes, 1 through 4. Also provided in the present invention are expression systems, plasmids and polynucleotide/ polypeptide fragments useful in generation of said monoclonal antibodies.
Disclosed herein is a tracer compound (3-fluoro[18F]azetidin-1-yl)(4-(oxazol-5-yl)-6-(trifluoromethyl)indolin-1-yl)methanone, derivative, or salt thereof and uses as an imaging agent. In certain embodiments, this disclosure relates to precursor compounds such as 1-(4-(oxazol-5-yl)-6-(trifluoromethyl)indoline-1-carbonyl)azetidin-3-yl 4-nitrobenzenesulfonate, derivative, or salt thereof and kits comprising the same.
C07D 209/26 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 209/56 - Ring systems containing three or more rings
C07D 263/02 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
36.
Bis-Biguanide Compounds, Pharmaceutical Compositions and Uses in Managing Cancer
This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
Goods & Services
Print publications, namely, manuals, instructional
materials, and curricula in the field of programs to
cultivate awareness, compassion, engagement, resilience
skills, and systems thinking in personal, community, and
global contexts. Educational services, namely, instruction and training in
the field of programs to cultivate awareness, compassion,
engagement, resilience skills, and systems thinking in
personal, community, and global contexts; providing online
publications, namely, manuals, instructional materials, and
curricula in the field of programs to cultivate awareness,
compassion, engagement, resilience skills, and systems
thinking in personal, community, and global contexts.
38.
Fluorination Methods of Arenes Using Arylbenziodoxolones and Compositions Related Thereto
Disclosed herein are tracer and precursor compounds for performing imaging methods such as positron emission tomography (PET). In certain embodiments, this disclosure relates to methods of forming 18F substituted aromatic compounds comprising contacting an aryl compound substituted with an aryl[d][1,2]iodaoxol-3-one group and a fluorine ion under conditions providing a fluorine aromatic compound with a fluorine in place of the aryl[d][1,2]iodaoxol-3-one group.
This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C07H 19/11 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
40.
MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES
This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain examples, modulators are derivatives of hexahydropental ene. In certain examples, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.
C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07C 307/08 - Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
41.
DIAZAQUINOLINES AND RELATED COMPOUNDS AS ANTIVIRAL AGENTS
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
EMORY UNIVERSITY (USA)
Inventor
Plemper, Richard K.
Cox, Robert
Lieber, Carolin M.
Natchus, Michael
Govindarajan, Mugunthan
Abstract
Disclosed herein are substituted isomeric naphthyridinyl benzamides and related compounds as broad-spectrum GHP-class polymerase inhibitors, and pharmaceutical compositions thereof, utilized for the treatment and prevention of viral infections. The inventive compounds may be used to treat a paramyxovirus infection, an orthoparamyxovirus infection, a respirovirus infection, a morbillivirus infection, or a henipavirus infection.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
Disclosed herein are antibodies that specifically bind vasoactive intestinal peptide (anti-VIP antibodies). In certain embodiments, chimeric anti-VIP antibody sequences are useful in the treatment human patients with VIP associated disorders or conditions such as hematological or solid cancers. In certain embodiments, this disclosure relates to vectors and cells that express anti-VIP antibodies disclosed herein, kits, and pharmaceutical compositions comprising the same.
This disclosure relates to devices and methods for signaling transient and mechanical events associated with ligand receptor interactions. In certain embodiments, this disclosure contemplates devices for detecting ligand receptor binding interactions using a pair of hybridized nucleic acids wherein a strand is conjugated to ligand and a complementary strand is conjugated to a solid support wherein upon dehybridization due to forces transmitted to the ligand-receptor complex, a surface immobilized single stranded nucleic acid is exposed and targeted by a Cas nuclease and guide RNA complex, and whereby the presence of a single stranded reporter nucleic acid is cleaved providing a signal.
Disclosed herein are methods of treating cancer comprising administering an effective amount of a probiotic bacteria to a human patient with cancer optionally in combination with a VIP antagonist. In certain embodiments, the cancer is a hematological cancer such as leukemia. In certain embodiments, the subject is diagnosed with acute myeloid leukemia. In certain embodiments, the probiotic bacteria increase long chain fatty acids in the lumen of the intestine. In certain embodiments, this disclosure relates to probiotic compositions for uses in treating or preventing cancer as reported herein.
A61K 35/66 - Microorganisms or materials therefrom
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
46.
Coronavirus Assays, Diagnostic Methods, Treatment Methods, and Compositions Related Thereto
This disclosure relates to coronavirus assays, diagnostic methods, treatment methods, and compositions related thereto. In certain embodiments, this disclosure relates to ACE2 receptor binding domain peptides and uses in serological assays and vaccination methods.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventor
Wan, Yong
Chi, Junlong
Bahar, Ivet
Cheng, Hongying
Abstract
Disclosed herein are pharmaceutical agents that inhibit MGAT1 and uses in managing diseases and conditions associated with MGAT1 interactions, such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering to a subject in need thereof an effective amount of a pharmaceutical agent that inhibits MGAT1 or suppress MGAT1 and CD73 binding interactions. In certain embodiments, the compound is N-(3-(5,6-dimethylbenzo[d]oxazol-2-yl)-4-hydroxy-5-methylphenyl)benzo[d][1,3]dioxole-5-carbox-amide (W-GTF01), derivative, prodrug, ester, or salt thereof.
C07D 317/48 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
This disclosure relates to compositions comprising glycolipid nanoparticles and a therapeutic comprising: a) ionizable lipid, b) poly(ethylene glycol) lipid, c) sterol, and d) glycolipid. In certain embodiments, the average diameter of the particles is about between 30 and 180 nm. In certain embodiments, the therapeutic is a nucleic acid encoding a therapeutic protein.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
The disclosed systems and methods use the developed Flexible Relaxation and Saturation Time (FIRST) approach to provide customization of parameters for a Magnetization Transfer (MT) sequences to maximize sensitivity and efficiency. The methods may include generating one or more customized parameters for one or more iterations of a Magnetization Transfer Magnetic Resonance (MR) sequence that is executed on a Magnetic Resonance Imaging (MRI) System. The generating may include receiving input parameters for each iteration of the sequence. The one or more input parameters may include radiofrequency (RF) offset and/or saturation power. The generating may further include determining a set of one or more customized parameters for each iteration using the input parameters for each RF offset and/or saturation power. The one or more customized parameters may include repetition time (TR).
G01R 33/54 - Signal processing systems, e.g. using pulse sequences
G01R 33/485 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information
G01R 33/50 - NMR imaging systems based on the determination of relaxation times
Disclosed herein are compounds having cystic fibrosis transmembrane conductance regulator modulatory activity. The compounds are useful for treating respiratory disorders, including cystic fibrosis.
A multisource interventional X-ray imaging system including a ring assembly is disclosed. The ring assembly may include a first arc including a plurality of X-ray sources, and a second arc including a plurality of detectors. The X-ray sources and the detectors may be arranged to view a patient. Further, the ring assembly may axially rotate or wobble by a maximum angular displacement that is equivalent to a distance between adjacent X-ray sources.
A microneedle has a proximal end portion and a distal end portion and defines a lumen. The proximal end portion is configured to be coupled to a cartridge to place the lumen in fluid communication with the cartridge. The proximal end portion includes a base surface that is configured to be placed in contact with a surface of a target tissue. The distal end portion of the microneedle includes a beveled surface. The beveled surface defines a tip angle of less than about 20 degrees and a ratio of a bevel height to a bevel width of less than about 2.5.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
53.
MINICIRCLE DNA PLATFORM FOR R-LOOP PRODUCTION AND VISUALIZATION
The present disclosure relates to methods for producing minicircle DNA (mcDNA) and methods of using the mcDNA as a scaffold to produce R-loops. Further disclosed are methods of screening for an agent that binds an R-loop.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
C12Q 1/6839 - Triple helix formation or other higher order conformations in hybridisation assays
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.
A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
EMORY UNIVERSITY (USA)
Inventor
Singh, Uma S.
Chu, Chung K.
Sarafianos, Stefanos
Abstract
The present invention relates to 2'-fluoro-6'-methylene carbocyclic nucleosides and nucleotides, pharmaceutical compositions containing these nucleosides and nucleotides, and their use in the treatment or prophylaxis of poxvirus infections and secondary disease states and conditions thereof.
The present disclosure relates to radiotracers that selectively bind to voltage-gated sodium channels (e.g., NaV1.7 or NaVl.8) and which are useful for detecting, imaging, and/or quantifying the NaVs, e.g., using positron-emission tomography (PET). The disclosure is also directed to processes for preparing the radiotracers, and to the use of the radiotracers for imaging a tissue or a subject, e.g., in vivo. The disclosure is further related to methods of pain management and improved identification and diagnosis allowing for rapidly identifying the location of or source of pain. The disclosure also relates to growth mediums, cell cultures, and kits.
C07D 237/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07B 59/00 - Introduction of isotopes of elements into organic compounds
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include enterovirus, tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
The present disclosure provides a system for treating melioidosis, comprising a first antimicrobial agent comprising trimethoprim at a subinhibitory concentration and a second antimicrobial agent comprising a FolE2 enzyme inhibitor selected from dehydrocostus lactone, parthenolide, or β-lapachone, wherein the combination of the first antimicrobial agent and the second antimicrobial agent exhibits chemical synthetic lethality against Burkholderia pseudomallei while having minimal effect on commensal bacteria. The subinhibitory concentration of trimethoprim ranges between 5 μM and 30 μM. The FolE2 enzyme inhibitor acts as a mechanism-based inhibitor that covalently modifies a catalytic cysteine residue (Cys154) of the FolE2 enzyme. The combination exhibits greater than 90% growth suppression against Burkholderia pseudomallei. Methods for treating melioidosis and identifying antimicrobial drug targets using chemical synthetic lethality screening approaches are also provided.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The addition of a tyrosine kinase inhibitor, including but not limited to imatinib, in a dosage regimen in combination with tecovirimat provides superior results in the treatment of orthopox infections, including monkeypox infections or monkeypox disease. The unexpected results show that the combined administration of imatinib and tecovirimat provides synergistic reduction of monkeypox spread.
60.
METHODS OF ANALYZING IMMUNOGLOBULIN AUTOANTIBODIES FOR DIAGNOSING RISK OF MICROBIAL DISEASE SEVERITY AND GUIDING THERAPY
Disclosed herein are methods of diagnosing a subject for a risk of developing severe coronavirus disease as correlated to the presence of IgA anti-IFN-alpha autoantibodies. In certain embodiments, the methods include the use of fluorescent beads that are used to analyze the presence of IgA1 and/or IgA2 anti-IFN-alpha autoantibodies and simultaneous measurement of IFN-α and CXCL10 in the same nasal sample. In certain embodiments, methods further comprise reporting the diagnosis to the subject or medical professional. In certain embodiment, methods further comprise administering a pharmaceutical agent to the subject.
This disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof which have uses in vaccination methods or therapeutic strategies. In certain embodiments, this disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof, comprising an arginine (R) at position 166, glutamine (Q) at position 170, and an amino acid histidine (H) at position 173. In certain embodiments, this disclosure relates to nucleic acids and recombinant vectors encoding said proteins.
Provided herein is a sensitive, quantitative, and scalable targeted proteomics assay of Alzheimer's Disease biomarkers representing neuronal, glial, vasculature and metabolic pathways. The biomarkers are protease-digested peptides selected from biological samples of individuals having normal Aβ and Tau levels (AT−) and from symptomatic and asymptomatic individuals having low Aβ and high Tau levels (AT+). The assay uses selective reaction monitoring-based mass spectrometry (SRM-MS) of peptides in the biological samples after digestion.
This disclosure relates to growth media and environments for in vitro culturing of cells that produce or are capable of producing antibodies. In certain embodiments, the media comprises tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ), fibronectin, and optionally with other ingredients disclosed herein. In certain embodiments, the disclosure contemplates enclosures comprising culture compositions disclosed herein that are in ambient air or optionally in an environment wherein oxygen is absent or at a low concentration.
The disclosure relates to Respiratory Syncytial Virus (RSV) vaccine compositions having truncated mucin domains in the G-protein. In certain embodiments, this disclosure relates to virus particles, virus-like particles, virosomes, nucleic acids, vectors, or attenuated live RSV vaccines for uses reported herein. In certain embodiments, this disclosure relates to methods of vaccinating, treating, or preventing RSV infections by administering to a subject in need thereof an effective amount of a composition disclosed herein.
Disclosed herein are beta-amino-ester and betathiol-ester containing polymers. In certain embodiments, the polymers comprise: monomers with a hydrophobic linker disubstituted with an alkane polyol; monomers of a branched thiol alkanoate; and monomers of an alkyl diamine. In certain embodiment, the polymer further comprises monomers of an amine alkyl acetal. In certain embodiment, the polymer further comprises monomers of an aminoalkyl carbamimidothioate. In certain embodiments, the polymers are used in methods of delivering a pharmaceutical agent to the lungs.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
C08G 63/685 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing nitrogen
C08G 75/045 - Polythioethers from mercapto compounds or metallic derivatives thereof from mercapto compounds and unsaturated compounds
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
66.
Parallel-Loading Microfluidic Devices for Rapid Diagnostic Assays, Systems, and Associated Methods
In some examples, the disclosure relates to a microfluidic device configured for rapid diagnostic assays. For example, the microfluidic device may include a common inlet channel. The device may also include a common outlet channel disposed parallel to the common inlet channel. The device may further include a plurality of testing pathways in fluid communication with and disposed between the common inlet channel and the common outlet channel. Each testing pathway may include a test chamber including a dried reagent mixture and a vent channel in fluid communication with the test chamber. The common inlet channel may be configured to divide a liquid sample input into each testing pathway.
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure, in some embodiments, relates to a method that includes accessing digitized imaging data stored in an electronic memory. The digitized imaging data comprises one or more regions of interest including pulmonary vein branches of a patient. A plurality of radiomic features are extracted from the one or more regions of interest. The plurality of radiomic features include one or more of fractal-based features or mesh-based features. The plurality of radiomic features are provided to a machine learning stage. The machine learning stage is configured to utilize the plurality of radiomic features to generate a medical prediction corresponding to atrial fibrillation recurrence after an ablation procedure.
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
The invention relates to dendritic cells loaded with nucleic acid sequences expressing cytokines and optionally other molecules, pharmaceutical compositions comprising such dendritic cells, and medical use of such dendritic cells and compositions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to dendritic cells loaded with nucleic acid sequences expressing checkpoint inhibitors and optionally other molecules, pharmaceutical compositions comprising such dendritic cells, and medical use of such dendritic cells and compositions.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This disclosure contemplates tagging cells or vesicles with agents using a tension activated device. In certain embodiments, a solid surface is conjugated to a double stranded nucleic acid complex wherein a first strand is conjugated to the surface containing a ligand, and a second strand is conjugated to a lipophilic agent. In certain embodiments, the first and/or second strand is conjugated to a label, e.g., fluorescent dye. In certain embodiments, a cell or vesicle comprising a receptor that binds to the ligand provides tension on the double stranded complex to denature the strands resulting the cell membrane associating with or incorporating the lipid conjugated strand.
This disclosure relates to methods of treating or preventing traumatic brain injury (TBI) or related conditions comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic polymer or a pharmaceutically acceptable salt thereof to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating chronic traumatic encephalopathy (CTE) comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic polymer, or a pharmaceutically acceptable salt thereof to subject in need thereof.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61P 25/00 - Drugs for disorders of the nervous system
73.
Molecular Tension Probes and Methods to Determine or Monitor the Efficacy of Cancer and Other Immune Therapies
This disclosure contemplates methods of detecting, measuring, and/or quantifying a tensional force on cells that express an antigen. In certain embodiments, this disclosure relates to methods and devices disclosed herein used to determine or monitor whether a cancer therapy or other immunotherapy is appropriate for a specific patient. In certain embodiments, the therapy is administering blinatumomab or other bispecific engager to a patient.
This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
75.
Systems and Methods for Automated Digital Phenotyping and Analysis of Bone Biopsy Images Using Deep Learning
In some examples, the disclosure relates to a digital phenotyping method. For example, the method may include operating upon digitized pathology image data of a bone sample from a patient with one or more models to generate one or more feature maps for one or more components. The one or models may include one or more deep learning models, one or more computer vision models, among others, or any combination thereof. In some examples,+ the one or more components may include osteoclast, osteoblast, bone marrow bone marrow adipose tissue (BMAT), mineralized bone, and/or osteoid.
G06V 30/199 - Arrangements for recognition using optical reference masks, e.g. holographic masks
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
76.
Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens
This disclosure contemplates detecting antimicrobial heteroresistance to guide antibiotic or other antimicrobial therapy. In certain embodiments, this disclosure contemplates avoiding a monotherapy with antibiotics to which an individual bacterial isolate is heteroresistant, because this can lead to treatment failure. Thus, in certain embodiments, one uses a combination of antibiotics to which a bacterium is individually heteroresistant.
A described example relates to a system that includes a microfluidic device and an impedance analyzer. The microfluidic device includes a microchannel extending through a portion of a housing. The microchannel is configured to receive a fluid sample including blood cells that flows along in a direction of fluid flow through the microchannel. The microchannel includes a plurality of micropillar arrays along the direction of fluid flow, and each of the plurality of micropillar arrays is located between a respective pair of electrodes in the microchannel. The impedance analyzer can be coupled to each of the electrodes and configured to measure electrical impedance of at least some of the micropillar arrays at multiple times, in a wash-free assay, including at least one impedance measurement before the fluid sample is flowing through the microchannel and at least one impedance measurement after the fluid sample is flowing through the microchannel.
This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed herein are prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role by administering a compound disclosed herein to a subject in need thereof.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The devices, systems, and methods can provide an automated, scalable NM-MRI approach to define regions, such as SNc and LC, and determine associated quantitative information, such as volume measurements. The methods may include generating an individualized region mask of a region of interest (ROI) of a brain region of an individual by converting a population region mask from standard space into individual space using the population region mask and MRI image data of the individual. In some examples, the method may further include generating an individualized reference ROI using the MRI image data. The method may further include segmenting the ROI from within the individualized region mask using information derived from the individualized reference ROI.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
82.
ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
C07H 19/02 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof sharing nitrogen
C07H 19/04 - Heterocyclic radicals containing only nitrogen as ring hetero atom
Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3- b)pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
C07C 49/683 - Unsaturated compounds containing a keto group being part of a ring containing six-membered aromatic rings having unsaturation outside the aromatic rings
C07C 49/83 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
C07C 215/70 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
C07C 255/47 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
C07C 271/34 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 307/02 - Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
In some embodiments, the systems and methods of the disclosure can rapidly and accurately determine the level of susceptibility of a sample to one or more antimicrobial agents using measured topography of that sample. The method may include providing a container including one or more sites having a sample and one or more concentrations of one or more antimicrobial agents. The method may include determining one or more metrics of at least a region of each site using the topographic surface profile for each site. The one or more metrics may include one or more of volumetric, distribution, spatial correlation, among others, or a combination thereof. The method may include determining one or more indices representing a level of susceptibility of the sample to the concentration of the one or more antimicrobial agents provided in each site using the one or more metrics for that site from one or more indices.
This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.
A61D 99/00 - Subject matter not provided for in other groups of this subclass
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
The United States Government as represented by the Department of Veterans Affairs (USA)
Emory University (USA)
Inventor
Patel, Jay Milan
Mauck, Robert L
Pepper, Tristan
Solomon, Hanna
Abstract
Hyaluronic acid-based polymers which can crosslink within joint tissue either by photo-crosslinking or chemical crosslinking to provide a hydrogel within the joint tissue to aid with joint tissue protection, regeneration, and repair.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
90.
Automated Cell Culture Systems, Devices, and Associated Methods
The automated cell culture systems, devices and methods can allow for better control of the chemical and biological environment while doing in vitro cell culture. In some examples, the system may include a main body having a top side, a bottom side, a first side, and a second side. In some examples, the main body may include one or more fluid channels. Each fluid channel may have a first end disposed at the first side and a second end disposed at the second side. Each channel may include an inlet at the first end and an outlet at the second end. Each channel may be defined by opposing side wall surfaces and a bottom surface region. Each inlet may be disposed at a first position along the first side closer to the top side than each outlet. Each bottom surface region may be sloped from the inlet to the outlet.
Disclosed are subunit-selective N-methyl-D-aspartic acid receptor (NMDAR) modulators. In some cases, the compounds are positive allosteric modulators of the GluN2 subunit. In some cases, the compounds are positive allosteric modulators of the GluN2 subunit and are selective for GluN2C/D over GluN2A. In some cases, the compounds are positive allosteric modulators of the GluN2 subunit and are selective for GluN2C/D over both GluN2A and GluN2B. The present disclosure also relates to pharmaceutical formulations of the subunit-selective NMDAR modulators as well as methods for treating conditions, disorders, or diseases using the disclosed compounds and pharmaceutical formulations.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
92.
SYSTEMS, DEVICES, AND METHODS FOR REDUCING HEART VALVE REGURGITATION
Embodiments described herein relate to an implant delivery system for delivering an implant for reducing heart valve regurgitation. The implant delivery system may include an implant catheter disposed in an inner lumen of a guide catheter. The implant catheter may include one or more hypotubes disposed therein, each hypotube configured to receive an elongate member such as a braided tether. A distal end of the implant catheter may be coupled to an implant holder configured to receive the implant. The implant holder may define one or more channels, each channel configured to receive a portion of a respective elongate member. The elongate members configured to couple the implant to the implant holder and transition the implant between configurations. The implant configured to be disposed around a portion of a leaflet of a heart valve to improve coaptation of the heart valve.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
In certain embodiments, this disclosure relates to conjugates including GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically, the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors including nucleic acid encoding polypeptide conjugates, and protein expression systems including these vectors such as infectious viral particles and host cells including such nucleic acids.
This disclosure relates to compounds that inhibit glutathione S-transferases (GSTs) and/or NAD(P)H:quinone oxidoreductase 1 (NQO1) for uses in treating cancer. In certain embodiments, this disclosure relates to compositions and uses of N-(thiazol-2-yl)-carboxamide derivatives such as a N-(5-nitrothiazol-2-yl)-carboxamide derivatives for treating cancer such as glioblastoma.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
An apparatus comprising, a major cannula, a first guiding channel, and a first minor cannula. The major cannula can comprise major cannula joints that enable articulation of the major cannula and major cannula tendons operatively coupled with at least a portion of the major cannula joints to control the articulation of the major cannula. The first guiding channel can extend through a portion of the major cannula and can define a first inlet for receiving a first minor cannula. The first minor cannula can comprise a first end and a second end, and the first end can be removably coupled to the first guiding channel. The first minor cannula can comprise minor cannula joints that enable articulation of the first minor cannula and minor cannula tendons operably coupled with at least a portion of the minor cannula joints to control the articulation of the first minor cannula.
A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
Described herein are systems and devices for recording a signal at a stimulating electrode. An example device includes a stimulator port operably connected to a stimulator decoupler stage; an input port operably connected to the stimulator decoupler stage and a current limiter stage, where the current limiter stage is configured to limit a current flowing from the input port to a recording port and where the stimulator decoupler stage is configured to prevent a loading effect on the recording amplifier inputs; a voltage range limiter stage operably connected to the current limiter stage and the recording port and configured to limit the voltage output to a predetermined recording amplifier range.
The present disclosure relates to anti-SARS-COV-1 and anti-SARS-COV-2 activatable RNase guide sequences and methods of use for screening, treating, and/or preventing SARS infections and/or COVID-related diseases.
This disclosure relates to recombinant immunoglobulin endoglycosidases. In certain embodiments, the recombinant immunoglobulin endoglycosidases comprise insertions and/or mutations disclosed herein. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising recombinant immunoglobulin endoglycosidases disclosed herein and/or nucleic acids or vector encoding the same. In certain embodiments, this disclosure relates to pharmaceutical compositions. In certain embodiments, this disclosure relates to recombinant immunoglobulin G-specific endoglycosidase CU43 comprising a dipeptide FK insertion at position 240 wherein the dipeptide FK insertion is in reference to positions in the CP40 amino acid sequence.
Disclosed herein are compositions and methods for managing viral infections. In certain embodiments, this disclosure relates to compositions that specifically cleave target sequences in viruses, such as dengue virus. Such compositions include lipid nanoparticles containing nucleic acids encoding a Cas guide-RNA associated endonuclease, with a guide sequence of a viral target sequence. In certain embodiments, contemplated methods include treating a viral infection by administering lipid nanoparticles (LNPs) comprising mRNA encoding Cas13a and a guide RNA or multiple guide RNAs that target regions of a dengue genome or other viral genome.
The present invention provides a compound useful for the treatment of microbial pathogens and related conditions, compositions and formulations comprising the compound thereof, and methods of treating using the compound thereof.
C07D 241/38 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
